Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial [Yahoo! Finance]
KIRIN HLDGS CO LTD S/ADR (KNBWY)
US:NASDAQ Investor Relations:
kirinholdings.co.jp/english/ir
Company Research
Source: Yahoo! Finance
therapy, rocatinlimab, aimed at treating adults and adolescents with moderate to severe atopic dermatitis (AD). The ASCEND trial is part of the expansive ROCKET Phase III clinical programme, which includes eight trials. These studies are designed to determine the efficacy and safety of various dosing schedules of the therapy for patients with moderate to severe AD. ASCEND involves approximately 2,600 subjects and focuses on assessing the long-term impact of rocatinlimab in 150mg and 300mg dosages, given to individuals at either four or eight-week intervals. The preliminary analysis concentrated on the adult population who had completed 24 weeks of treatment in an earlier ROCKET trial and continued with ASCEND for an additional 32 weeks. The primary goal of the trial was to assess the long-term safety of the therapy, with secondary endpoints assessed in adults who demonstrated a clinical response in the HORIZON or IGNITE studies and were subsequently re-randomised in ASCEND.
Show less
Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNBWY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNBWY alerts
High impacting KIRIN HLDGS CO LTD S/ADR news events
Weekly update
A roundup of the hottest topics
KNBWY
News
- Kirin (TSE:2503): Assessing Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Kyowa Kirin (TSE:4151): Evaluating Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Kura Oncology wins FDA approval for leukemia drug [Seeking Alpha]Seeking Alpha
- The World's Two Best Bourbons Dominate The IWSC Honor Roll [Forbes]Forbes
- Is Kirin (KNBWY) Stock Outpacing Its Consumer Staples Peers This Year? [Yahoo! Finance]Yahoo! Finance